![FPO Tower](/sites/default/files/styles/subscription_callout/public/2021-07/img-pittwire-subscribe.png?h=7f3918f9&itok=hC3ZYfSz)
Subscribe to Pittwire Today
Get the most interesting and important stories from the University of Pittsburgh.Mark Shlomchik was elected as a Distinguished Fellow of the AAI
![School of Medicine building sign behind tree](/sites/default/files/styles/small_article_image/public/2022-05/20210414_ao_bucher_tree_0013_smallhero.jpg?h=d8076212&itok=oRZsp9UR)
UPMC Endowed and Distinguished Professor Mark Shlomchik was elected as a 2024 Distinguished Fellow of the American Association of Immunologists (AAI). It is among the highest honors bestowed by the AAI.
The Distinguished Fellowship recognizes active, long-term members who have demonstrated excellence in research accomplishment in the field of immunology, exceptional leadership to the immunology community in academia at a national or international level and notable distinction as an educator.
Shlomchik — who also co-founded and served as chief scientific officer at Bluesphere Bio, a translational sciences company developing therapies that harness the immune response of patients to cure cancer — chaired the Department of Immunology in Pitt’s School of Medicine from 2013-22. He has made several fundamental contributions to understanding autoimmune diseases and immune responses, most recently in a Nature Immunology study that explains the developmental origins of memory B cells, which underly how vaccines and post-infection immunity are protective.